1. Home
  2. Browse
  3. HRA001554
HRA001554
   HRA001554.xlsx
Title:
Durable complete response to pembrolizumab in esophageal squamous-cell carcinoma with divergent microsatellite status: A Case Report
Release date:
2021-11-17
Description:
A Chinese esophageal squamous cell carcinoma (ESCC) patient with unusual divergent MSI status between the primary lesion (MSS) and metastatic lesion (MSI-H) which developed after Q10 platinum-based therapy and radiotherapy.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA007220
Study type:
Disease Study
Disease name:
esophageal basaloid squamous cell carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC000934
DAC name:
Esophageal cancer
Contact person:
He Ji
Email:
he.ji@genecast.com.cn
Description:
A Chinese esophageal squamous cell carcinoma (ESCC) patient with unusual divergent MSI status between the primary lesion (MSS) and metastatic lesion (MSI-H) which developed after Q10 platinum-based therapy and radiotherapy.
Individuals & samples
Files
Request Data
Submitter:   He Ji / he.ji@genecast.com.cn
Organization:   Company Name: Genecast Biotechnology Co., Ltd
Submission date:   2021-11-17
Requests:   -